Table 1.
Treatment history of the left eye
| Date | Number of days between visits | Description | VA | ETDRS letters | CFT, microns |
|---|---|---|---|---|---|
| 13/07/2009 | 224 | Proliferative retinopathy diagnosed | NN | NN | NN |
| 14/08/2009 | 32 | Panretinal laser photocoagulation | 6/6 | 85 | NN |
| 21/10/2009 | 68 | Quiecscent laser-treated retinopathy | 6/6 | 85 | NN |
| 20/10/2010 | 364 | Diffuse DME diagnosed | 6/36 | 46 | 712 |
| 19/11/2010 | 30 | IVTA injection | NN | NN | NN |
| 14/12/2010 | 25 | Underwent macular grid | 6/18 | 61 | 304 |
| 25/01/2011 | 42 | Visit | 6/18 | 61 | 283 |
| 02/03/2011 | 36 | Visit | 6/12 | 70 | 279 |
| 18/01/2012 | 322 | Dense cataract | 6/36 | 46 | 612 |
| 02/02/2012 | 15 | Phacoemulsification; +IOL; IVTA to treat cataract and recurrent DME | NN | NN | NN |
| 16/04/2012 | 74 | Visit | 6/12 | 70 | 278 |
| 31/08/2012 | 137 | Visit | 6/36 | 46 | 769 |
| 24/09/2012 | 24 | Visit; admitted into the Matisse trial (ranibizumab + siRNA agent) | 6/30 | 50 | 805 |
| 08/10/2012 | 14 | 1st study injection | NN | NN | NN |
| 12/11/2012 | 35 | 2nd study injection | 6/15 | 65 | 352 |
| 10/12/2012 | 28 | 3rd study injection | 6/12 | 70 | 279 |
| 07/01/2013 | 28 | 4th study injection | 6/9 | 76 | 271 |
| 04/02/2013 | 28 | 5th study injection | 6/9 | 76 | 304 |
| 04/03/2013 | 28 | Visit | 6/9 | 76 | 332 |
| 08/04/2013 | 35 | Patient exits study listed for ranibizumab injection due to residual and progressive DME | 6/12 | 70 | 577 |
| 06/06/2013 | 59 | Ranibizumab injection | NN | NN | NN |
| 09/07/2013 | 33 | Ranibizumab injection | NN | NN | NN |
| 23/08/2013 | 45 | Ranibizumab injection | NN | NN | NN |
| 07/09/2013 | 15 | Visit | 6/36 | 46 | 451 |
| 17/10/2013 | 40 | Ranibizumab injection | NN | NN | NN |
| 21/11/2013 | 35 | Ranibizumab injection | NN | NN | NN |
| 10/01/2014 | 50 | Ranibizumab injection | NN | NN | NN |
| 03/03/2014 | 52 | Visit | 6/24 | 55 | 774 |
| 21/03/2014 | 18 | ILUVIEN injection | NN | NN | NN |
| 28/03/2014 | 7 | Visit | 6/18 | 61 | 267 |
| 04/04/2014 | 7 | Visit | 6/12 | 70 | 241 |
| 06/06/2014 | 63 | Visit | 6/12 | 70 | 234 |
| 04/09/2014 | 90 | Visit | 6/12 | 70 | 245 |
| 30/09/2014 | 26 | Visit | 6/18 | 61 | 245 |
| 01/02/2015 | 124 | Visit | 6/12 | 70 | 239 |
| 28/03/2015 | 55 | Visit | 6/18 | 61 | 240 |
| 08/05/2015 | 41 | Visit | 6/6 | 85 | 251 |
| 25/09/2015 | 140 | Visit | 6/9 | 76 | 252 |
| 24/10/2015 | 29 | Visit | 6/18 | 61 | NN |
| 28/01/2016 | 96 | Visit | 6/12 | 70 | 250 |
| 02/03/2016 | 34 | Visit | 6/12 | 70 | NN |
| 06/04/2016 | 94 | Visit | 6/12 | 70 | 250 |
VA, visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; CFT, central foveal thickness; IVTA, intravitreal triamcinolone acetonide; NN, no numbers; IOL, intraocular lens; siRNA, small-interfering RNA; DME, diabetic macular oedema.